Skip to main content
. 2015 May 4;10(5):e0126217. doi: 10.1371/journal.pone.0126217

Fig 9. LY294002 inhibits the HYS-32-induced phosphorylation of GSK3β-pS9 and GSK3β-pY216.

Fig 9

(A) Control astrocytes (Con) or astrocytes treated for 24 h with 5 μM HYS-32 (HYS), co-treated for 24 h with 5 μM HYS-32 and 20 μM LY294002 (HYS+LY), or treated with 20 μM LY294002 (LY) were subjected to 10% SDS-PAGE, and analyzed by immunoblotting with antibodies against GSK3β-pSer9, GSK3β-pY216, totalGSK3β, or GAPDH. (B) Densitometric analyses of GSK3β-pSer9 and GSK3β-pY216 expressed as the density of the bands in the treated groups relative to the control. (C) According to the data in (B), the stacked bar graph showing relative percentage ofphospho-GSK3β in various treatment. (D)Astrocytes treated as in (A) were fixed in cold acetone and triple-stained for β-tubulin, N-cadherin, and F-actin. Quantitative analysis of the straight distance between microtubule tips and cell border were performed as described in Materials and Methods. The results were collected from three independent experiments.*p<0.01 compared to HYS using one-way ANOVA with Dunnett’s post-hoctest.